Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
about
Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewHIV-1 drug resistance and resistance testing.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileIn vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.Elvitegravir: a review of its use in adults with HIV-1 infection.Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant virusesAntiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.Different Pathways Leading to Integrase Inhibitors ResistanceHIV drug resistance against strand transfer integrase inhibitorsThe M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa.
P2860
Q26853055-69643C45-C2E7-4F6A-A20F-F7A3C4E7F079Q30245693-E2368C05-D42D-41F4-9267-B761D3E0782AQ34540677-357E16C1-CD94-4193-8136-7D703F231D83Q35083423-82070584-019E-4DBC-8716-7E6315C26F9AQ35169003-A3F80DB3-18FB-4827-865D-ED1E8D343DB7Q36284159-545B5719-F6BE-47F0-B2D2-767CB94C71BDQ37473023-5897B8AD-EA20-4DE7-86A4-3E61ED18CC03Q38199659-D4C59DBD-5987-43E1-B66E-248D897C2789Q38774333-8E555A2F-A116-4D76-96F2-3B6F47FC931CQ38943015-653F7A92-934E-4EDE-AF50-8D740DA7941BQ39103603-04B9E72F-2520-4724-840F-2FC0F14BB6E2Q39352571-797DE524-2699-4003-A25B-6A116BDDA4A7Q41884057-6E94CE3F-B7F0-46B0-9BD3-1EC10C4785BFQ41926589-3426E735-2D1C-4D1C-9C3B-6F125ACDA5ECQ52352259-3AE20CAA-77BB-4494-BF05-F23581BABEA3
P2860
Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Multiple genetic pathways invo ...... ss-resistance to elvitegravir.
@en
Multiple genetic pathways invo ...... ss-resistance to elvitegravir.
@nl
type
label
Multiple genetic pathways invo ...... ss-resistance to elvitegravir.
@en
Multiple genetic pathways invo ...... ss-resistance to elvitegravir.
@nl
prefLabel
Multiple genetic pathways invo ...... ss-resistance to elvitegravir.
@en
Multiple genetic pathways invo ...... ss-resistance to elvitegravir.
@nl
P2093
P2860
P356
P1476
Multiple genetic pathways invo ...... ss-resistance to elvitegravir.
@en
P2093
Arne Frantzell
Signe Fransen
P2860
P304
P356
10.1128/AAC.00204-13
P407
P577
2013-06-03T00:00:00Z